The first drug potentially covered by the expanded plan, Leqembi, could be granted full approval from the Food and Drug Administration as soon as this summer.
The drug, donanemab, is the latest treatment to target amyloid beta, a protein that builds up in the brain and is a signature characteristic of Alzheimer’s.
For years, doctors and patients thought there was little to do when dementia was diagnosed, even at an early stage. Now, potentially sweeping changes loom.